|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The present study did not find any significant association of NQO1 609C>T and NQO2 -3423G>A polymorphisms with susceptibility to EC or its clinical phenotypes (histopathology, tumor location or lymph node metastasis) or interactions with lifestyle risk factors (tobacco usage, smoking, alcohol habit and occupational exposures).
|
22770696 |
2012 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The rate of strong positive NQO1 protein expression was correlated with large tumor size (P=0.019), late pathologic stage (P=0.001) and the presence of lymph node metastasis (P=0.001).
|
25231218 |
2014 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Therefore, our findings support that NQO1 displays a paradoxical role in mediating GBM growth in response to tumor suppressor PTEN.
|
30595797 |
2018 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
These data indicate that the NQO1 609C>T polymorphism results in significantly reduced tumor NQO1 activity and reduced survival in subsets of patients receiving intraperitoneal hyperthermic mitomycin C therapy.
|
11773862 |
2002 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These data suggest that RH1 may be an effective NQO1-directed antitumor agent for the therapy of tumors with elevated NQO1 activity, such as NSCLC.
|
9865924 |
1998 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
These results support the ideas that reductive activation of MMC by DTD may be important in the cytotoxicity of MMC and that polymerase chain reaction may be a useful technique for quantitating the relative expression of genes in human tumors.
|
1737339 |
1992 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
They can be activated by DT-diaphorase and hence can be used to target tumour types rich in this (O2)-independent reductase enzyme.
|
12052210 |
2002 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
This genomic gain was associated with amplification of the NQO1 gene in one tumor biopsy as well as in breast cancer cell lines.
|
26687450 |
2016 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
This translational study offers a potential biomarker-driven strategy using NQO1 expression to select tumors susceptible to β-lap-induced radiosensitization.
|
27196777 |
2016 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
This was transfected into the human colon BE tumor line, which has a disabling point mutation in NQO1.
|
11040064 |
2000 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We found that NQO1 was frequently up-regulated in human liver cancer, and its high expression level was correlated with the tumor stage and low survival rate of HCC patients.
|
30867140 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We measured expression levels of three different reductase enzymes-DT-diaphorase [NAD(P)H (i.e., reduced nicotinamide adenine dinucleotide, with or without phosphate): quinone oxidoreductase]; NADPH:cytochrome P-450 reductase; and NADH (i.e., reduced nicotinamide adenine dinucleotide): cytochrome-b5 reductase- in 69 cell lines (most of the National Cancer Institute [NCI] human tumor cell panel) to see if relationships could be established between the activities of these enzymes and cellular sensitivities to the bioreductive compounds mitomycin C and EO9.
|
8614004 |
1996 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We show elevated NAD(P)H:quinone oxidoreductase-1 (NQO1) levels in tumors from NSCLC patients. beta-Lapachone, an effective chemotherapeutic and radiosensitizing agent, selectively killed NSCLC cells that expressed high levels of NQO1.
|
17609380 |
2007 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
When the NQO1-proficient A549 tumors and NQO1-deficient MDA-MB-231 tumors were developed in the same animal, only the A549 malignancies activated the NIR-ASM probe with a strong signal.
|
31189950 |
2019 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Xenografts established from the clonal lines exhibited significant tumor control following MMC treatment (treated/control [T/C] 17% and 51% for DTD and P450R xenografts, respectively) that was not seen in wild-type tumors (T/C 102%).
|
14555709 |
2003 |